Keyword Analysis & Research: amg 510 kras g12c inhibitor

nih.gov

https://pubmed.ncbi.nlm.nih.gov/31666701/

Author: Jude Canon, Karen Rex, Anne Y. Saiki, Christopher Mohr, Keegan Cooke, Dhanashri Bagal, Kevin Gaida, ... Publish Year: 2019

Author: Jude Canon, Karen Rex, Anne Y. Saiki, Christopher Mohr, Keegan Cooke, Dhanashri Bagal, Kevin Gaida, ...

Publish Year: 2019

DA: 57 PA: 18 MOZ Rank: 90

nature.com

https://www.nature.com/articles/s41586-019-1694-1

Oct 30, 2019 · KRAS (G12C) inhibition by AMG 510 also led to an accumulation of active EGFR (p-EGFR (Y1068)). Inhibition of AKT phosphorylation (p-AKT) was apparent in one cell line, … Author: Jude Canon, Karen Rex, Anne Y. Saiki, Christopher Mohr, Keegan Cooke, Dhanashri Bagal, Kevin Gaida, ... Is Accessible For Free: False Publish Year: 2019

Author: Jude Canon, Karen Rex, Anne Y. Saiki, Christopher Mohr, Keegan Cooke, Dhanashri Bagal, Kevin Gaida, ...

Is Accessible For Free: False

Publish Year: 2019

DA: 1 PA: 57 MOZ Rank: 27

nih.gov

https://pubmed.ncbi.nlm.nih.gov/31820981/

Biopharmaceutical optimization of the resulting leads culminated in the identification of AMG 510, a highly potent, selective, and well-tolerated KRAS G12C inhibitor currently in phase I clinical … Author: B.A. Lanman, J.R. Allen, J.G. Allen, A.K. Amegadzie, K.S. Ashton, S.K. Booker, J.J. Chen, N. Chen, M... Publish Year: 2019

Author: B.A. Lanman, J.R. Allen, J.G. Allen, A.K. Amegadzie, K.S. Ashton, S.K. Booker, J.J. Chen, N. Chen, M...

Publish Year: 2019

DA: 72 PA: 77 MOZ Rank: 6

esmo.org

https://www.esmo.org/oncology-news/discovery-of-amg-510-a-first-in-class-oral-kras-g12c-inhibitor

The research efforts have led to the discovery of AMG 510, the first KRAS G12C inhibitor in clinical development. On 30 October 2019, the investigators published in the Nature an article …

DA: 86 PA: 54 MOZ Rank: 7

medchemexpress.com

https://www.medchemexpress.com/AMG-510.html

Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound … Cell Line: NCI-H358 and MIA PaCa-2 cells Incubation Time: 72 hours Concentration: 1-10 μM

Cell Line: NCI-H358 and MIA PaCa-2 cells

Incubation Time: 72 hours

Concentration: 1-10 μM

DA: 7 PA: 60 MOZ Rank: 51

amgen.com

https://www.amgen.com/newsroom/press-releases/2019/10/the-discovery-of-amgens-novel-investigational-krasg12c-inhibitor-amg-510-published-in-nature

Titled "The Clinical KRAS G12C Inhibitor AMG 510 Drives Anti-Tumor Immunity," the paper highlights novel structural insights that led to the discovery of AMG 510, the preclinical …

DA: 42 PA: 15 MOZ Rank: 71

amgen.com

https://www.amgen.com/newsroom/press-releases/2019/06/amgen-announces-first-clinical-data-evaluating-novel-investigational-krasg12c-inhibitor-amg-510-at-asco-2019

Jun 03, 2019 · AMG 510 is the First KRASG12C Inhibitor to Reach Clinical Stage After Three Decades of RAS Research. First-In-Human Results Show Preliminary Safety, Tolerability Data …

DA: 26 PA: 38 MOZ Rank: 72

lww.com

https://journals.lww.com/oncology-times/Fulltext/2019/11050/Trial_of_Irreversible_KRASG12C_Inhibitor_AMG_510.10.aspx

AMG 510 is an irreversible inhibitor of the mutant KRAS G12C protein. Mechanistically, it undergoes a rapid reaction and forms a covalent bond with the thiol moiety of the cysteine-12 …

DA: 29 PA: 26 MOZ Rank: 47

nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041424/

Both AMG 510 from Amgen and MRTX849 from Mirati Therapeutics covalently binds to KRAS G12C at the cysteine at residue 12, keeping KRAS G12C in its inactive GDP-bound state and …

DA: 86 PA: 36 MOZ Rank: 55

acs.org

https://www.acs.org/content/dam/acsorg/events/drug-discovery/slides/2021-02-25-ddds1-sotorasib.pdf

Feb 25, 2021 · The Discovery of Sotorasib (AMG 510): First-in-Class Investigational Covalent Inhibitor of KRAS G12C Presentation slides are available now! The edited recording will be …

DA: 90 PA: 59 MOZ Rank: 39